Nov. 2 - Sanofi continues dealmaking with cell therapy buyout | A warning sign for a Regeneron rare disease drug

Regeneron pauses study of rare disease drug following patient deaths; AstraZeneca partners with Fusion to test radiopharmaceuticals in cancer View online | Signup | Forward

Daily Dive Nov.​ 2,​ 2020 | Today's news and insights for biopharma leaders   BROUGHT TO YOU BY — Marken Reach more patients with our depot network Our global infrastructure supports the evolving demands of the clinical trial ecosystem. Store clinical drugs closer to key recruitment areas, reach patients faster, and keep your trials on track. Learn more.   Revamp pays off for Kiadis with $358M Sanofi buyout The Dutch biotech labored for years developing a better stem cell transplant until 2019, when it switched focus to cancer-fighting cell therapies. Regeneron pauses study of rare disease drug following patient deaths The company hasn't determined whether its drug played a role in the deaths, but concerns over the treatment's safety could dim its chances for approval. Sponsored Content by ZS How pharma can move forward during significant disruptions to the healthcare field ZS experts share three steps you can take to successfully evolve your commercial model. Read more. AstraZeneca partners with Fusion to test radiopharmaceuticals in cancer While small in size, the collaboration gives AstraZeneca an entry point into radiopharmaceutical drug research, which was the focus of two Novartis buyouts in recent years. Read more news Featured Resources FROM: MilliporeSigma Risk Mitigation Strategies You Must Know Now Optimize your analytical program for greater risk reduction Balancing speed and risk when time is of the essence: Proven strategies to accelerate drug development Establish the optimal balance between risk, cost and speed through flexible, custom CDMO solutions From Our Library Trendline Trends and Developments in Real-World Evidence View all resources What We're Reading Axios Health care industry has evaded major changes under Trump FierceBiotech Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio BioCentury Expanding access to COVID-19 vaccines Bloomberg Pfizer and Mylan to Sell Assets, Gain Clearance for Deal Suggest a story we should read Upcoming Events Transforming the Pharma Supply Chain with Blockchain Nov. 11, 2020 - Nov. 11, 2020 | Webinar 2pm ET Optimizing IRT Design and Management to Future Proof Your Trial Nov. 17, 2020 - Nov. 17, 2020 | Webinar 11am ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip